Imo I just can't imagine the same drug being licenced out to a dozen or more pharmas for 50+ different indications. At best it will be one pharma for each region for all indications but they won't have the synergy of a global BP. It would not be for the best interest of the patients. Trofinitide only has 2 indications on the table and I doubt it will be further developed once NNZ 2591 passes phase 3. The current licencing structure works for DayBue but probably not for 2591
- Forums
- ASX - By Stock
- NEU
- Share Price
Share Price, page-8570
-
-
- There are more pages in this discussion • 3,246 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$13.55 |
Change
-0.260(1.88%) |
Mkt cap ! $1.726B |
Open | High | Low | Value | Volume |
$13.82 | $13.91 | $13.51 | $2.297M | 168.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
13 | 655 | $13.54 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.55 | 323 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
9 | 1088 | 13.510 |
17 | 8432 | 13.500 |
10 | 704 | 13.490 |
7 | 1087 | 13.480 |
5 | 7678 | 13.470 |
Price($) | Vol. | No. |
---|---|---|
13.520 | 1074 | 16 |
13.530 | 406 | 6 |
13.540 | 717 | 6 |
13.550 | 356 | 4 |
13.560 | 919 | 6 |
Last trade - 13.56pm 11/09/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |